Affymax (OTCMKTS: AFFY) and ContraFect Corporation (NASDAQ:CFRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Affymax and ContraFect Corporation, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Affymax 0 0 0 0 N/A
ContraFect Corporation 0 1 1 0 2.50

ContraFect Corporation has a consensus price target of $5.00, indicating a potential upside of 385.44%. Given ContraFect Corporation’s higher probable upside, analysts clearly believe ContraFect Corporation is more favorable than Affymax.

Valuation and Earnings

This table compares Affymax and ContraFect Corporation’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Affymax $41,999.00 27.76 -$47.65 million N/A N/A
ContraFect Corporation N/A N/A -$28.65 million ($0.49) -2.10

ContraFect Corporation has higher revenue, but lower earnings than Affymax.


This table compares Affymax and ContraFect Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Affymax N/A N/A N/A
ContraFect Corporation N/A -188.40% -84.04%

Risk and Volatility

Affymax has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Comparatively, ContraFect Corporation has a beta of -0.82, meaning that its stock price is 182% less volatile than the S&P 500.

Insider & Institutional Ownership

24.5% of ContraFect Corporation shares are held by institutional investors. 1.6% of Affymax shares are held by company insiders. Comparatively, 9.3% of ContraFect Corporation shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.


ContraFect Corporation beats Affymax on 5 of the 9 factors compared between the two stocks.

Affymax Company Profile

Affymax, Inc. is a biopharmaceutical company. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.

ContraFect Corporation Company Profile

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

Receive News & Stock Ratings for Affymax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymax Inc. and related stocks with our FREE daily email newsletter.